Inactive Instrument

Neon Therapeutics, Inc. Stock price

Equities

US64050Y1001

Biotechnology & Medical Research

Dynamic Chart
Neon Therapeutics, Inc. Announces Management Changes CI
Neon Therapeutics, Inc.(NasdaqGS:NTGN) dropped from S&P TMI Index CI
BioNTech SE completed the acquisition of Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others. CI
Transcript : Neon Therapeutics, Inc. - Shareholder/Analyst Call
Neon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Neon Therapeutics, Inc. Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01 CI
Neon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019 CI
BioNTech SE entered into an Agreement to acquire Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others for $73.6 million. CI
Neon Therapeutics, Inc. Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01 CI
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs; to Reduce Workforce by Approximately 24% of Current Headcount CI
Neon Therapeutics Intends to Explore Strategic Alternatives CI
Neon Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Neon Therapeutics, Inc. Presents Updated Data at the Society for Immunotherapy of Cancer's 34th Annual Meeting in National Harbor, MD CI
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens CI
Neon Therapeutics, Inc. Provides Business Update CI
More news
Managers TitleAgeSince
President 74 16-10-31
Human Resources Officer - 17-08-15
More insiders
Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.
More about the company
  1. Stock
  2. Equities
  3. Stock Neon Therapeutics, Inc. - Nasdaq